{
  "symbol": "AMGN",
  "year": 2024,
  "period": "Q3",
  "curated_text": "Symbol: AMGN. Year: 2024. Period: Q3. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Litigation Amgen Inc., Sandoz Inc., the U.S. District Court, Sandoz, FDA, Amgen, the New Jersey District Court, Amgen\u2019s \u2018736 Patent, the United States Sandoz, the \u2019736 Patent, ABP, the Judicial Panel on Multidistrict Litigation, Regeneron, District Court, the Delaware District Court, the U.S. Court of Appeals, the Third Circuit, the Third Circuit Court, the Third Circuit Court\u2019s, U.S. Tax Litigation, Related Matters Amgen Inc. & Subsidiaries, IRS, Company, the U.S. Tax Court, ChemoCentryx, the Ninth Circuit, ANALYSIS OF FINANCIAL CONDITION, MD&A, SEC, EPS. Context excerpt: Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infringement of patents listed in the FDA\u2019s Purple Book for Amgen\u2019s Prolia and XGEVA products. A preliminary injunction hearing, held between October 30 and December 21, 2023, focused on a composition of matter patent U.S. Patent No. 7,364,736 (the \u2018736 Patent) and two manufacturing patents. The judgment entered by the New Jersey District Court found the asserted claims of Amgen\u2019s \u2018736 Patent valid, enforceable and infringed by Sandoz\u2019s biosimilar denosumab products and included an injunction prohibiti",
  "competition_summary": [
    {
      "competitor": "Litigation Amgen Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Sandoz Inc.",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the U.S. District Court",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Sandoz",
      "mentions": 6,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "FDA",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Amgen",
      "mentions": 8,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the New Jersey District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Amgen\u2019s \u2018736 Patent",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the United States Sandoz",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the \u2019736 Patent",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "ABP",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Judicial Panel on Multidistrict Litigation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Regeneron",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "District Court",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Delaware District Court",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the U.S. Court of Appeals",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Third Circuit",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Third Circuit Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Third Circuit Court\u2019s",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "U.S. Tax Litigation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Related Matters Amgen Inc. & Subsidiaries",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "IRS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Company",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the U.S. Tax Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "ChemoCentryx",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Ninth Circuit",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "ANALYSIS OF FINANCIAL CONDITION",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "MD&A",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "SEC",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "EPS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    }
  ]
}